Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
8.81
+0.39 (4.63%)
At close: Dec 5, 2025, 4:00 PM EST
8.70
-0.11 (-1.25%)
After-hours: Dec 5, 2025, 7:46 PM EST
Verrica Pharmaceuticals Employees
Verrica Pharmaceuticals had 71 employees as of December 31, 2024. The number of employees decreased by 29 or -29.00% compared to the previous year.
Employees
71
Change (1Y)
-29
Growth (1Y)
-29.00%
Revenue / Employee
$434,211
Profits / Employee
-$366,394
Market Cap
140.87M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VRCA News
- 12 days ago - Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway - GlobeNewsWire
- 19 days ago - Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 26 days ago - Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire
- 6 weeks ago - Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 6 weeks ago - Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum - GlobeNewsWire